Download PDF
Am J Perinatol 2024; 41(S 01): e3187-e3195
DOI: 10.1055/s-0043-1777445
Original Article

Feasibility of Universal Screening for Preeclampsia Risk and Aspirin Recommendation in the Ultrasound Unit

Verónica Maria Pimentel 
1   Department of Obstetrics and Gynecology, Saint Francis Hospital and Medical Center, Hartford Connecticut
2   Department of Obstetrics and Gynecology, Frank H. Netter School of Medicine, Quinnipiac University, North Haven, Connecticut
3   Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut
,
Alexander D. Almeida Larrea
1   Department of Obstetrics and Gynecology, Saint Francis Hospital and Medical Center, Hartford Connecticut
,
Sophie J. Renaud
2   Department of Obstetrics and Gynecology, Frank H. Netter School of Medicine, Quinnipiac University, North Haven, Connecticut
,
Sophie Sloan
1   Department of Obstetrics and Gynecology, Saint Francis Hospital and Medical Center, Hartford Connecticut
,
Reinaldo Figueroa 
1   Department of Obstetrics and Gynecology, Saint Francis Hospital and Medical Center, Hartford Connecticut
2   Department of Obstetrics and Gynecology, Frank H. Netter School of Medicine, Quinnipiac University, North Haven, Connecticut
,
Dorothy Wakefield
4   Department of Research, Saint Francis Hospital and Medical Center, Hartford, Connecticut
,
Rebecca Crowell
4   Department of Research, Saint Francis Hospital and Medical Center, Hartford, Connecticut
› Author Affiliations Funding This study received grant for statistical support from the March of Dimes.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective To evaluate the feasibility and impact of using the first-trimester ultrasound visit to identify and counsel women at increased risk of preeclampsia about the benefits of low-dose aspirin (LDA) for preventing preeclampsia. We also assessed patient-reported utilization of LDA, perceived risk for preeclampsia, and clinical outcomes.

Study Design Women presenting for routine first-trimester nuchal-translucency (NT) ultrasounds were screened for clinical preeclampsia risks using a self-administered risk assessment. Women at moderate or high risk for preeclampsia were counseled to take LDA, if not already taking it. LDA utilization and perceived risk for preeclampsia were assessed during the second-trimester ultrasound. Factors associated with LDA utilization were analyzed. Pregnancy outcomes were compared between those who used LDA and those who did not.

Results Slightly more than 20% of patients (765/3,669) screened at increased risk for developing preeclampsia. Of those, 67.8% (519/765) had not received LDA recommendations from their referring obstetrician and 97 had not been taking LDA despite being advised to do so. Combined, 94.6% (583/616) of these patients eligible to start LDA prophylaxis received the indicated counseling during the ultrasound visit. A total of 61.4% (358/583) of women completed the follow-up form and of those 77.9% (279/358) reported taking LDA. Screening at increased risk for preeclampsia and perception of increased risk were positively associated with LDA utilization, whereas concerns for LDA safety were negatively associated with use. African American/Black patients and Medicaid recipients were less likely to use LDA. Pregnancy outcomes were similar between those who used LDA and those who did not.

Conclusion Assessing preeclampsia risk and counseling patients about LDA at the time of the NT ultrasound are feasible in the ultrasound unit and led to good LDA utilization among women at increased risk for preeclampsia. This intervention may standardize patient care and help close the disparity in maternal health.

Key Points

  • A simple intervention captured 2/3 of eligible patients.

  • Aspirin utilization rate was good after the intervention.

  • Screening high risk for preeclampsia and self-perception of risk correlated with aspirin use.

Keywords

low-dose aspirin - aspirin utilization - preeclampsia - risk assessment - pregnancy - ultrasound unit

Note

Some of the data were presented virtually at the Society for Maternal-Fetal Medicine 41st Annual Pregnancy Meeting, Poster #281, January 28, 2021.




Publication History

Received: 07 March 2023

Accepted: 12 November 2023

Article published online:
15 December 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol 2020; 135 (06) e237-e260
    CrossrefPubMedGoogle Scholar
  • 2 Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2021; 326 (12) 1192-1206
    CrossrefPubMedGoogle Scholar
  • 3 American College of Obstetricians and Gynecologists. Low-dose aspirin use during pregnancy. ACOG committee opinion no. 743. Obstet Gynecol 2018; 132 (01) 254-256
    CrossrefPubMedGoogle Scholar
  • 4 Davidson KW, Barry MJ, Mangione CM. et al; US Preventive Services Task Force. Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force recommendation statement. JAMA 2021; 326 (12) 1186-1191
    CrossrefPubMedGoogle Scholar
  • 5 Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369 (9575) 1791-1798
    CrossrefPubMedGoogle Scholar
  • 6 CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343 (8898) 619-629
    CrossrefPubMedGoogle Scholar
  • 7 Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018; 218 (03) 287-293.e1
    CrossrefPubMedGoogle Scholar
  • 8 Shanmugalingam R, Wang XS, Chau K. et al. A cohort study utilising a biochemical assessment of aspirin compliance vs resistance in high-risk pregnant women. Pregnancy Hypertens 2018; 13: S82-S83
    CrossrefPubMedGoogle Scholar
  • 9 Werner EF, Hauspurg AK, Rouse DJ. A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet Gynecol 2015; 126 (06) 1242-1250
    CrossrefPubMedGoogle Scholar
  • 10 Wright D, Poon LC, Rolnik DL. et al. Aspirin for evidence-based preeclampsia prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol 2017; 217 (06) 685.e1-685.e5
    CrossrefPubMedGoogle Scholar
  • 11 Xu TT, Zhou F, Deng CY, Huang GQ, Li JK, Wang XD. Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis. J Clin Hypertens (Greenwich) 2015; 17 (07) 567-573
    CrossrefPubMedGoogle Scholar
  • 12 Bujold E, Roberge S, Lacasse Y. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 (2 Pt 1): 402-414
    CrossrefPubMedGoogle Scholar
  • 13 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622
    CrossrefPubMedGoogle Scholar
  • 14 van Montfort P, Scheepers HCJ, van Dooren IMA. et al. Low-dose-aspirin usage among women with an increased preeclampsia risk: a prospective cohort study. Acta Obstet Gynecol Scand 2020; 99 (07) 875-883
    CrossrefPubMedGoogle Scholar
  • 15 Olson DN, Russell T, Ranzini AC. Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. Am J Obstet Gynecol MFM 2022; 4 (05) 100663
    CrossrefPubMedGoogle Scholar
  • 16 Lewkowitz AK, Rouse DJ. Miscommunication about low-dose aspirin for preeclampsia prevention-further support for universal prophylaxis. JAMA Netw Open 2021; 4 (10) e2130960
    CrossrefPubMedGoogle Scholar
  • 17 Krishnamurti T, Davis AL, Rodriguez S, Hayani L, Bernard M, Simhan HN. Use of a smartphone app to explore potential underuse of prophylactic aspirin for preeclampsia. JAMA Netw Open 2021; 4 (10) e2130804
    CrossrefPubMedGoogle Scholar
  • 18 Boelig RC, Wanees M, Zhan T, Berghella V, Roman A. Improving utilization of aspirin for prevention of preeclampsia in a high-risk urban cohort: a prospective cohort study. Am J Perinatol 2021; 38 (06) 544-552
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 LeFevre ML. U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 161 (11) 819-826
    CrossrefPubMedGoogle Scholar
  • 20 Gestational Hypertension and Preeclampsia. Gestational hypertension and preeclampsia: ACOG practice bulletin summary, number 222. Obstet Gynecol 2020; 135 (06) 1492-1495
    CrossrefPubMedGoogle Scholar
  • 21 Ferrer R, Klein WM. Risk perceptions and health behavior. Curr Opin Psychol 2015; 5: 85-89
    CrossrefPubMedGoogle Scholar
  • 22 Dillard AJ, Midboe AM, Klein WM. The dark side of optimism: unrealistic optimism about problems with alcohol predicts subsequent negative event experiences. Pers Soc Psychol Bull 2009; 35 (11) 1540-1550
    CrossrefPubMedGoogle Scholar
  • 23 Wheeler SM, Myers SO, Swamy GK, Myers ER. Estimated prevalence of risk factors for preeclampsia among individuals giving birth in the US in 2019. JAMA Netw Open 2022; 5 (01) e2142343
    CrossrefPubMedGoogle Scholar
  • 24 Kim C, McEwen LN, Piette JD, Goewey J, Ferrara A, Walker EA. Risk perception for diabetes among women with histories of gestational diabetes mellitus. Diabetes Care 2007; 30 (09) 2281-2286
    CrossrefPubMedGoogle Scholar
  • 25 Gray KL, McKellar LM, O'Reilly SL, Clifton PM, Keogh JB. Women's barriers to weight loss, perception of future diabetes risk and opinions of diet strategies following gestational diabetes: an online survey. Int J Environ Res Public Health 2020; 17 (24) 1-12
    CrossrefPubMedGoogle Scholar
  • 26 Hoffman MK, Goudar SS, Kodkany BS. et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet 2020; 395 (10220): 285-293
    CrossrefPubMedGoogle Scholar
  • 27 Guy GP, Leslie K, Diaz Gomez D. et al. Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study. BJOG 2021; 128 (02) 149-156
    CrossrefPubMedGoogle Scholar
  • 28 Health Division A. The California Pregnancy-associated Mortality Review Report from 2002 to 2007 Maternal Death Reviews; 2018 . Accessed January 24, 2023 at: https://www.cdph.ca.gov/Programs/CFH/DMCAH/CDPH%20Document%20Library/PAMR/CA-PAMR-Report-1.pdf
    PubMedGoogle Scholar
  • 29 Hoyert DL. Maternal mortality rates in the United States, 2020. NCHS Health E-Stats 2022. DOI: 10.15620/cdc:113967 Accessed January 24, 2023 at: https://www.cdc.gov/nchs/data/hestat/maternal-mortality/2020/E-stat-Maternal-Mortality-Rates-2022.pdf
    CrossrefPubMedGoogle Scholar
  • 30 Centers for Disease Control and Prevention. 2022, June 22. Pregnancy mortality surveillance system. Accessed January 24, 2023 at: https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm
    PubMedGoogle Scholar
  • 31 Boakye E, Kwapong YA, Obisesan O. et al. Nativity-related disparities in preeclampsia and cardiovascular disease risk among a racially diverse cohort of US women. JAMA Netw Open 2021; 4 (12) e2139564
    CrossrefPubMedGoogle Scholar
  • 32 Centers for Disease Control and Prevention. Working together to reduce Black maternal mortality 2022. Accessed January 24, 2023 at: https://www.cdc.gov/healthequity/features/maternal-mortality/index.html#:~:text=Black%20women%20are%20three%20times,structural%20racism%2C%20and%20implicit%20bias
    PubMedGoogle Scholar
  • 33 Poon LC, Shennan A, Hyett JA. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145 (Suppl 1, Suppl 1) 1-33
    CrossrefPubMedGoogle Scholar
  • 34 Combs CA, Montgomery DM. SMFM Patient Safety and Quality Committee. Electronic address: smfm@smfm.org. Society for Maternal-Fetal Medicine Special Statement: checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin. Am J Obstet Gynecol 2020; 223 (03) B7-B11
    CrossrefPubMedGoogle Scholar
  • 35 Malone SL, Haj Yahya R, Kane SC. Reviewing accuracy of first trimester screening for preeclampsia using maternal factors and biomarkers. Int J Womens Health 2022; 14: 1371-1384
    CrossrefPubMedGoogle Scholar
  • 36 O'Gorman N, Wright D, Poon LC. et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol 2017; 49 (06) 756-760 Erratum in: Ultrasound Obstet Gynecol 2017;50(6):807
    CrossrefPubMedGoogle Scholar